{"type":"img","src":"https://cdn.quv.kr/dftb6ow8k%2Fup%2F5c32ea85dae40_1920.png","height":90}
  • COMPANY
  • R&D PIPELINE
  • CRO SERVICES
  • CAREER
  • NEWS
  • CONTACT US
  • {"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Noto Sans KR","Nanum Barun Gothic"]}
    ×
    섹션 설정
    {"type":"img","src":"https://cdn.quv.kr/dftb6ow8k%2Fup%2F5c32ea85dae40_1920.png","height":50}
  • COMPANY
  • R&D PIPELINE
  • CRO SERVICES
  • CAREER
  • NEWS
  • CONTACT US
  • New drug candidate for chronic and neuropathic pain

    RCI 002

     RCI002

     

     

    Superior results when compared to Gabapentin for continous, long lasting analgesic effect

     

    ▪ TRPV1 antagonist

    ▪ Goal of L/O after Phase 1 / 2a Clinical Studies

    ▪ Being developed as a peptide treatment

    ▪ Non-opioid analgesic treatment

     

    RCI002



    Better than Gabapentin for continuous analgesic actioncandidate substance for painkillers indicating efficacy


    ▪ TRPV1 antagonist

    ▪ Goal of L/O after Phase 1 / 2a of Clinical Practic

    ▪ Development of peptide treatments


    {"google":["Noto Sans","Poppins"],"custom":["Noto Sans KR","Nanum Square","Nanum Barun Gothic","Jeju Gothic"]}{"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR","Jeju Gothic"]}
    {"google":[],"custom":["Noto Sans KR","Jeju Gothic"]}